FDA Issues Qualified Health Claim Related to Yogurt, Type 2 Diabetes
By Denny Jacob
The U.S. Food and Drug Administration doesn't intend to object to certain health claims surrounding yogurt and type 2 diabetes.
The FDA said in a letter of enforcement discretion that it won't object to certain qualified health claims related to yogurt consumption and reduced risk of type 2 diabetes provided that the qualified health claims are worded in a way that doesn't mislead consumers, among other considerations.
A qualified health claim is supported by scientific evidence but doesn't meet the more rigorous "significant scientific agreement" standard required for an authorized health claim, the regulator said.
The FDA responded to a qualified health claim petition submitted on behalf of Danone North America. After reviewing the petition and other evidence related to the claim, it determined that there is some credible evidence supporting a relationship between yogurt intake and reduced risk of type 2 diabetes but that the evidence is limited.
"We know that a growing body of research suggests regular yogurt consumption could reduce your risk of developing one of the most significant and rapidly rising health ailments in the United States. That's why we decided to submit a petition for this first-of-its-kind qualified health claim," said Miguel Freitas, vice president of health and scientific affairs at Danone North America.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 01, 2024 15:57 ET (20:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth